We are live on ! Find out more
AST.WS

Asterias Biotherapeutics Warrants

Delisted

AST.WS was delisted on the 26th of September, 2017.

37 hedge funds and large institutions have $72.2K invested in Asterias Biotherapeutics Warrants in 2016 Q2 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
37
Holders Change
+37
Holders Change %
–
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
37
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AST.WS Hedge Fund Activity: Q2 2016 in Review

37 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Warrants (AST.WS) for Q2 2016, worth a combined $72.2K.

Buyers outnumbered sellers: 37 funds opened new AST.WS positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $95.3K.

  • 37 institutional investors held Asterias Biotherapeutics Warrants (AST.WS) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $72.2K of Asterias Biotherapeutics Warrants stock for Q2 2016.
  • 37 funds opened new Asterias Biotherapeutics Warrants positions in Q2 2016 and 0 closed out, a net change of +37 holders.
  • The largest Asterias Biotherapeutics Warrants buyer in Q2 2016 was Fidelity Investments, an estimated $95.3K added.

Based on aggregated 13F filings for Q2 2016.